시장보고서
상품코드
1654277

비만 치료 시장 규모, 점유율, 동향 분석 리포트 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Obesity Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 153 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비만 치료 시장의 성장과 동향 :

세계의 비만 치료 시장 규모는 2030년에 605억 3,000만 달러에 달할 것으로 예측되며, 2025-2030년에 CAGR 22.31%로 성장할 것으로 예측됩니다.

Institute of Health Metrics and Evaluation에 따르면 전 세계 인구의 약 30.0%가 비만 또는 과체중이며, 좌식 생활방식, 운동 부족, 건강에 해로운 식습관 증가 추세는 비만의 높은 보급을 유발하는 중요한 요인입니다.

또한 체중 관리를 위한 솔루션이 출시되고, 업계 기업이 도입한 기술 발전과 정부가 시행한 지원 구상은 비만과 건강에 미치는 영향에 대해 더 많은 인식을 불러일으키고 있습니다. 이는 비만 치료 시장의 성장을 더욱 촉진하고 있습니다.

체중 관리에는 식이요법, 운동요법, 약물요법, 저침습적 장비 및 임플란트, 수술 등 다양한 접근법이 있습니다. 일반적인 약물 중에서는 복합제가 가장 큰 시장 점유율을 차지하고 있지만, 포만감을 주는 포만제가 비만 치료 시장에서 가장 빠르게 성장하고 있는 분야입니다.

수술 분야에서는 위 우회술이 가장 큰 성장 부문을 형성하고 있는 반면, 포만감 장비나 위 배출 장비와 같은 임플란트나 장비를 외과적으로 설치하는 저침습 내시경 수술 분야가 가장 빠르게 성장하고 있습니다.

민간 부문의 치열한 경쟁은 민간 병원 및 클리닉에서 제공되는 비만 치료의 최신 기술 개발을 위한 발전과 혁신을 촉진하고 있습니다. 그 결과, 최소침습적 수술에 대한 수요가 빠르게 증가하고 있습니다. 또한 비만 및 관련 질환에 대한 인식이 높아지고 체중 관리 솔루션의 상용화가 비만 치료 시장을 촉진하고 있습니다.

비만 치료 시장 보고서 하이라이트

  • 약물의 유형로는 GLP-1 수용체 작용제, 리파제 억제제, 식욕억제제, 기타 약물의 유형로 분류됩니다.
  • 투여 경로에 따라 비만 치료 시장은 비경구 및 경구로 분류됩니다.
  • 유통 채널은 병원약국, 소매 약국, 기타로 분류됩니다.
  • 기타 약국은 예측 기간 중 상당한 성장이 예상됩니다.
  • 북미 비만 치료 시장은 2024년 73.39%의 매출 점유율로 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 비만 치료 시장의 변수, 동향, 범위

  • 모시장 전망
  • 보조 시장의 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비만 치료 분석 툴
    • Porter의 산업 분석
    • PESTEL 분석

제4장 비만 치료 시장 : 약제 클래스 추정·동향 분석

  • 비만 치료 시장 : 약제 클래스 부문 대시보드
  • 비만 치료 시장 : 약제 클래스별 변동 분석
  • GLP-1 수용체 작용제
    • Semaglutide(Wegovy)
    • Liraglutide(Saxenda)
    • Tirzepatide(Zepbound)
  • 리파아제 저해제
  • 식욕 억제제
  • 기타 약제 클래스

제5장 비만 치료 시장 : 투여 경로 추정·동향 분석

  • 비만 치료 시장 : 투여 경로 부문 대시보드
  • 비만 치료 시장 : 투여 경로별 변동 분석
  • 비경구
  • 경구

제6장 비만 치료 시장 : 유통 채널 추정·동향 분석

  • 비만 치료 시장 : 유통 채널 부문 대시보드
  • 비만 치료 시장 : 유통 채널의 변동 분석
  • 병원 약국
  • 소매 약국
  • 기타

제7장 비만 치료 시장 : 지역 추정·동향 분석

  • 비만 치료 시장 점유율, 지역별
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 노르웨이
    • 스웨덴
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트
    • 남아프리카공화국

제8장 경쟁 구도

  • 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
  • 기업 분류
  • 기업 시장 점유율 분석, 2024년
  • 기업 히트맵 분석, 2024년
  • 기업 개요
    • Novo Nordisk A/S.
    • GSK plc.
    • VIVUS LLC
    • Currax Pharmaceuticals
    • Boehringer Ingelheim International GmbH
    • Rhythm Pharmaceuticals, Inc.
    • Gelesis
    • Eli Lilly and Company.
KSA 25.03.13

Obesity Treatment Market Growth & Trends:

The global obesity treatment market size is expected to reach USD 60.53 billion in 2030 and is anticipated to grow at a CAGR of 22.31% from 2025 to 2030. The upward trend in sedentary lifestyles, physical inactivity, and unhealthy food habits are the vital factors responsible for the high prevalence of obesity. According to the Institute of Health Metrics and Evaluation, about 30.0% of the global population is either obese or overweight.

Additionally, along with commercial availability of solutions for weight management, technological advancements introduced by the vertical players and supportive initiatives undertaken by the governments, create more awareness with regard to obesity and its impact on health. This is further driving the growth of the obesity treatment market.

There are various approaches for weight management such as diet, exercise, drugs, minimally invasive devices & implants, and surgeries. Amongst the prevalent drugs, the combination drugs hold the largest market share whereas satiety drugs that provide a feeling of fullness appear as the fastest-growing segment in the obesity treatment market.

In surgeries, gastric bypass procedures form the largest growing segment whereas the minimally invasive endoscopic procedure segment that involves surgical placement of implants and devices, such as satiety devices and gastric emptying devices, is the fastest-growing space.

Intense competition in the private sector has driven advancements and innovation toward the development of the latest techniques for obesity treatment that are offered in private hospitals and clinics. As a result, the demand for minimally invasive procedures is swiftly increasing. In addition, increasing awareness of obesity & the associated diseases and the commercial availability of weight management solutions is propelling the obesity treatment market.

Obesity Treatment Market Report Highlights:

  • Based on drug class, the industry has been categorized into GLP-1 receptor agonists, lipase inhibitors, appetite suppressants, and other drug classes
  • Based on the route of administration, the obesity treatment market has been categorized into parenteral and oral
  • Based on distribution channels, the market has been categorized into hospital pharmacies, retail pharmacies, and others.
  • The other pharmacies are expected to grow at a considerable growth of over the forecast period
  • North America obesity treatment market dominated the global industry with a revenue share of 73.39% in 2024

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Obesity Treatment Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of obesity-related conditions
      • 3.3.1.2. Government regulations and guidelines
      • 3.3.1.3. Advancements in treatment options
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Side effects and adverse reactions
      • 3.3.2.2. High cost of anti-obesity drugs
  • 3.4. Obesity Treatment Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Obesity Treatment Market: By Drug Class Estimates & Trend Analysis

  • 4.1. Obesity Treatment Market: Drug Class Segment Dashboard
  • 4.2. Obesity Treatment Market: By Drug Class Movement Analysis, USD Million, 2024 & 2030
  • 4.3. GLP-1 Receptor Agonists
    • 4.3.1. GLP-1 Receptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Semaglutide (Wegovy)
      • 4.3.2.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Liraglutide (Saxenda)
      • 4.3.3.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Tirzepatide (Zepbound)
      • 4.3.4.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lipase Inhibitors
    • 4.4.1. Lipase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Appetite Suppressants
    • 4.5.1. Appetite Suppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Drug Class
    • 4.6.1. Other Drug Class Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Obesity Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Obesity Treatment Market: Route of Administration Segment Dashboard
  • 5.2. Obesity Treatment Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
  • 5.3. Parenteral
    • 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Obesity Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Obesity Treatment Market: Distribution Channel Segment Dashboard
  • 6.2. Obesity Treatment Market: Distribution Channel Movement Analysis, USD Million, 2024 & 2030
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Obesity Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Obesity Treatment Market Share, By Region, 2024 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Obesity Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa Obesity Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Novo Nordisk A/S.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. GSK plc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. VIVUS LLC
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Currax Pharmaceuticals
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Boehringer Ingelheim International GmbH
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
    • 8.5.6. Rhythm Pharmaceuticals, Inc.
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Recent Developments/ Strategic Initiatives
    • 8.5.7. Gelesis
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Recent Developments/ Strategic Initiatives
    • 8.5.8. Eli Lilly and Company.
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Recent Developments/ Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제